Papageorge A G, Willumsen B M, Johnsen M, Kung H F, Stacey D W, Vass W C, Lowy D R
Mol Cell Biol. 1986 May;6(5):1843-6. doi: 10.1128/mcb.6.5.1843-1846.1986.
Microinjection of monoclonal antibody Y13-259, which reacts with all known mammalian and yeast ras-encoded proteins, has previously been shown to prevent NIH 3T3 cells from entering the S phase (L. S. Mulcahy, M. R. Smith, and D. W. Stacey, Nature [London] 313:241-243, 1985). We have now found several transformation-competent mutant v-rasH genes whose protein products in transformed NIH 3T3 cells are not immunoprecipitated by this monoclonal antibody. These mutant proteins are, however, precipitated by a different anti-ras antibody. Each of these mutants lacks Met-72 of v-rasH. In contrast to the result for cells transformed by wild-type v-rasH, Y13-259 microinjection of NIH 3T3 cells transformed by these mutant ras genes did not prevent the cells from entering the S phase. These results imply that a transformation-competent ras gene can supply a normal essential function for NIH 3T3 cells. When the proteins encoded by the mutant ras genes were overproduced in Escherichia coli, several mutant proteins that lacked Met-72 failed to bind Y13-259 in a Western blot. However, a ras protein from a mutant lacking amino antibody, but a ras protein from a mutant lacking amino acids 72 to 84 did not. These results suggest that Y13-259 may bind to a higher ordered structure that has been restored in the mutant lacking amino acids 72 to 82.
先前的研究表明,显微注射与所有已知哺乳动物和酵母ras编码蛋白发生反应的单克隆抗体Y13 - 259可阻止NIH 3T3细胞进入S期(L. S. 马尔卡希、M. R. 史密斯和D. W. 斯泰西,《自然》[伦敦]313:241 - 243, 1985)。我们现在发现了几个具有转化能力的突变型v - rasH基因,其在转化的NIH 3T3细胞中的蛋白质产物不能被这种单克隆抗体免疫沉淀。然而,这些突变蛋白可被另一种抗ras抗体沉淀。这些突变体中的每一个都缺失v - rasH的Met - 72。与野生型v - rasH转化的细胞结果相反,向这些突变ras基因转化的NIH 3T3细胞显微注射Y13 - 259并不能阻止细胞进入S期。这些结果表明,一个具有转化能力的ras基因可以为NIH 3T3细胞提供正常的必需功能。当突变ras基因编码的蛋白质在大肠杆菌中过量表达时,几个缺失Met - 72的突变蛋白在蛋白质印迹中未能与Y13 - 259结合。然而,一个缺失72至84位氨基酸的突变体的ras蛋白不能结合该抗体,但一个缺失72至82位氨基酸的突变体的ras蛋白能结合。这些结果表明,Y13 - 259可能与在缺失72至82位氨基酸的突变体中恢复的更高阶结构结合。